Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells
暂无分享,去创建一个
Hiroshi Yamamoto | H. Yamamoto | H. Yonekura | Y. Yamamoto | S. Yamagishi | H. Fujimori | Yasuhiko Yamamoto | Sho-ichi Yamagishi
[1] Hiroshi Yamamoto,et al. Advanced Glycation End Products-driven Angiogenesis in Vitro , 1997, The Journal of Biological Chemistry.
[2] H. Yamamoto,et al. Participation of c-met in the progression of human gastric cancers: anti-c-met oligonucleotides inhibit proliferation or invasiveness of gastric cancer cells. , 1996, Cancer gene therapy.
[3] L. Iacoviello,et al. Glucose and insulin independently reduce the fibrinolytic potential of human vascular smooth muscle cells in culture , 1996, Diabetologia.
[4] Nigel Mackman,et al. Elevated Cyclic AMP Inhibits NF-κB-mediated Transcription in Human Monocytic Cells and Endothelial Cells* , 1996, The Journal of Biological Chemistry.
[5] V. Martina,et al. PAI-1 reduction after treatment with glutathione in NIDDM , 1996 .
[6] Hiroshi Yamamoto,et al. Advanced glycosylation end products stimulate the growth but inhibit the prostacyclin‐producing ability of endothelial cells through interactions with their receptors , 1996, FEBS letters.
[7] Yasuhiko Hayashi,et al. Possible Participation of Autocrine and Paracrine Vascular Endothelial Growth Factors in Hypoxia-induced Proliferation of Endothelial Cells and Pericytes (*) , 1995, The Journal of Biological Chemistry.
[8] H. Yamamoto,et al. Receptor-mediated toxicity to pericytes of advanced glycosylation end products: a possible mechanism of pericyte loss in diabetic microangiopathy. , 1995, Biochemical and biophysical research communications.
[9] 畠山 治彦. Vascular aldosterone : biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells , 1995 .
[10] Hiroshi Yamamoto,et al. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. , 1994 .
[11] A. Schmidt,et al. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[12] Y. Zou,et al. Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.
[13] H. Yamamoto,et al. Endothelin 1 mediates endothelial cell-dependent proliferation of vascular pericytes. , 1993, Biochemical and biophysical research communications.
[14] H. Yamamoto,et al. Vascular pericytes not only regulate growth, but also preserve prostacyclin-producing ability and protect against lipid peroxide-induced injury of co-cultured endothelial cells. , 1993, Biochemical and biophysical research communications.
[15] E. Cagliero,et al. Increased Expression of Tissue Plasminogen Activator and Its Inhibitor and Reduced Fibrinolytic Potential of Human Endothelial Cells Cultured in Elevated Glucose , 1992, Diabetes.
[16] S. Dawson,et al. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review. , 1992, Atherosclerosis.
[17] L. Nelles,et al. Interaction of AP-1-, AP-2-, and Sp1-like proteins with two distinct sites in the upstream regulatory region of the plasminogen activator inhibitor-1 gene mediates the phorbol 12-myristate 13-acetate response. , 1992, Journal of Biological Chemistry.
[18] R. Bucala,et al. Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.
[19] P. Bosma,et al. Role of protein kinase C and cyclic adenosine monophosphate in the regulation of tissue-type plasminogen activator, plasminogen activator inhibitor-1, and platelet-derived growth factor mRNA levels in human endothelial cells. Possible involvement of proto-oncogenes c-jun and c-fos. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.
[20] H. Yasuda,et al. Purification and characterization of tissue plasminogen activator secreted by human embryonic lung diploid fibroblasts, IMR-90 cells. , 1991, Agricultural and biological chemistry.
[21] K. Hajjar,et al. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. , 1991, The Journal of biological chemistry.
[22] H. Vlassara. Chronic Diabetic Complications and Tissue Glycosylation: Relevant Concern for Diabetes-Prone Black Population , 1990, Diabetes Care.
[23] G. Lowe,et al. Tissue Plasminogen Activator Inhibition in Diabetes Mellitus , 1989, Diabetes Care.
[24] E. Levin,et al. Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells. , 1988, The Journal of biological chemistry.
[25] A. Cerami,et al. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.
[26] J. Auwerx,et al. Tissue‐Type Plasminogen Activator Antigen and Plasminogen Activator Inhibitor in Diabetes Mellitus , 1988, Arteriosclerosis.
[27] M. Blombäck,et al. PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION , 1987, The Lancet.
[28] D. Loskutoff,et al. Structure of the human plasminogen activator inhibitor 1 gene: nonrandom distribution of introns. , 1987, Biochemistry.
[29] B. Binder,et al. Nonenzymatic glucosylation as a contributing factor to defective fibrinolysis in diabetes mellitus. , 1986, Haemostasis.
[30] J. Paramo,et al. Postoperative Changes in the Plasmatic Levels of Tissue-Type Plasminogen Activator and Its Fast-Acting Inhibitor - Relationship to Deep Vein Thrombosis and Influence of Prophylaxis , 1985, Thrombosis and Haemostasis.
[31] F. Werf,et al. Plasminogen activator inhibitor in the blood of patients with coronary artery disease. , 1985, British medical journal.
[32] R. S. Kent,et al. Effect of hydrogen peroxide on prostaglandin production and cellular integrity in cultured porcine aortic endothelial cells. , 1985, The Journal of clinical investigation.
[33] P. Verde,et al. The human urokinase-plasminogen activator gene and its promoter. , 1985, Nucleic acids research.
[34] E. Kruithof,et al. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. , 1984, Blood.
[35] K. Pritchard,et al. Restoration of Prostacyclin/Thromboxane A2 Balance in the Diabetic Rat: Influence of Dietary Vitamin E , 1982, Diabetes.
[36] R. Gorman,et al. Regulation of endothelial cell cyclic nucleotide metabolism by prostacyclin. , 1981, The Journal of clinical investigation.
[37] C. Dollery,et al. CIRCULATING PROSTACYCLIN MAY BE REDUCED IN DIABETES , 1979, The Lancet.
[38] Daniel L. McGee,et al. Diabetes and cardiovascular disease. The Framingham study. , 1979, JAMA.
[39] J. Vane,et al. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. , 1978, Pharmacological reviews.
[40] M. M. Bradford. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.
[41] P. Lefèbvre,et al. [Eye and the diabetes mellitus]. , 1971, Archives d'ophtalmologie et revue generale d'ophtalmologie.
[42] B. Binder,et al. Plasminogen Activation in Diabetes mellitus , 1988 .
[43] A. Cerami,et al. The biochemistry of the complications of diabetes mellitus. , 1981, Annual review of biochemistry.